<DOC>
	<DOCNO>NCT01142700</DOCNO>
	<brief_summary>Based 12-week on-treatment data , least 1 dose BMS-824393 identify safe , well tolerate , sufficient antiviral activity progress late stage clinical trial combine pegIFNα/RBV treatment chronically infect hepatitis C virus genotype 1 treatment-naive subject .</brief_summary>
	<brief_title>A Study BMS-824393 Combination With Peginterferon Alfa-2a ( Pegasys ) Ribavirin ( Copegus ) Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Treatmentnaive subject genotype 1 chronic HCV HCV RNA ≥ 100,000 IU/mL screen Seronegative HIV HBsAg Liver biopsy within prior 2 year demonstrate cirrhosis Any evidence liver disease hepatitis C Diagnosed suspect hepatocellular carcinoma Laboratory value : neutrophil count &lt; 1500 cells/μL , platelet count &lt; 90,000/μL ; Hemoglobin ≤ 12 g/dL ( 120g/L ) woman ≤ 13 g/dL ( 130 g/L ) men Cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>